RT Journal Article
SR Electronic
T1 Does place connectivity moderate the association between concentrated disadvantage and COVID-19 fatality in the United States?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.06.22276053
DO 10.1101/2022.06.06.22276053
A1 Jing, Fengrui
A1 Li, Zhenlong
A1 Qiao, Shan
A1 Zhang, Jiajia
A1 Olatosi, Bankole
A1 Li, Xiaoming
YR 2022
UL http://medrxiv.org/content/early/2022/06/06/2022.06.06.22276053.abstract
AB Concentrated disadvantaged areas have been disproportionately affected by COVID-19 outbreak in the United States (US). Meanwhile, highly connected areas may contribute to higher human movement, leading to higher COVID-19 cases and deaths. This study examined whether place connectivity moderated the association between concentrated disadvantage and COVID-19 fatality. Using COVID-19 fatality over four time periods, we performed mixed-effect negative binomial regressions to examine the association between concentrated disadvantage, Twitter-based place connectivity, and county-level COVID-19 fatality, considering potential state-level variations. Results revealed that concentrated disadvantage was significantly associated with an increased COVID-19 fatality. More importantly, moderation analysis suggested that place connectivity significantly exacerbated the harmful effect of concentrated disadvantage on COVID-19 fatality, and this significant moderation effect increased over time. In response to COVID-19 and other future infectious disease outbreaks, policymakers are encouraged to focus on the disadvantaged areas that are highly connected to provide additional pharmacological and non-pharmacological intervention policies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by National Institutes of Health (grant number: 3R01AI127203-04S1), National Science Foundation (grant number: 2028791) and University of South Carolina COVID-19 Internal Funding Initiative (grant number: 135400-20-54176). The funders had no role in study design, data collection and analysis, decision to publish or preparation of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/nytimes/covid-19-data https://www.census.gov/programs-surveys/acs/data.html